novo-company-financing-28.html
Novo Annual Report 2015
29 / 72
portfolio company achievements in
2015
business news adaptimmune was listed on nasdaq in may
2015
. alder biopharmaceuticals raised more than
usd
200
million
in a follow-on offering in june
2015
. akebia therapeutics partnered japanese and certain other asian rights to mitsubishi tanabe pharma for vadadustat for
usd
100
million
, plus future milestone and royalty payments. colucid pharmaceuticals was listed on nasdaq in may
2015
. htg molecular diagnostics was listed on nasdaq in may
2015
. kanyos completed a build-to-buy option deal with astellas to collaborate in the fields of type 1 diabetes and celiac disease. nevro issued a public offering resulting in an aggregate proceed of approximately
usd
240
million
. obseva completed a chf 60
million
financing. otonomy closed a follow-on public offering for a total gross proceeds of approximately
usd
86
million
. spinifex pharmaceuticals was sold to novartis in
2015
. tobira was listed on nasdaq via reverse merger with regado biosciences and secured a
usd
70
million
financing. product news acacia pharma obtained positive phase 2b data in chemotherapy-induced nausea and vomiting with amisulpride. apollo endosurgery received pma approval for obera ® balloon. kalvista pharmaceuticals completed first-in-patient study in diabetic macular oedema with kvd001, a plasma kallikrein inhibitor. nevro received fda approval for senza ® , the spinal cord stimulation system for chronic back and leg pain. ophthotech has completed enrolment of two phase 3 trials and top-line data are expected by the end of 2016. otonomy obtained fda approval for otiprio as a treatment of middle ear effusion. tarsa therapeutics filed a nda for oral calcitonin seeking an osteoporosis indication. unchained labs acquired a portfolio of complementary products for protein formulation and stability analysis. annual review
2015
29 novo ventures
boston-biotech-companies-30.html
